3rd Quarter - Report

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Firm
Client
Income
—
Expenses
$320,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Animals ANI

H.R. 1607, Fairness to Pet Owners Act of 2019

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Small Business Administration (SBA); Internal Revenue Service (IRS); Labor, Dept of (DOL); White House Office; SENATE; Office of Natl Drug Control Policy (NDCP); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Drug Enforcement Administration (DEA); Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: H.R. 1607 (116th)

Taxation/Internal Revenue Code TAX

S. 172/H.R. 1398, Health Insurance Tax Relief Act of 2019; S. 215/H.R. 218, Death Tax Repeal Act of 2019; S. 1089/ H.R. 1922, Restoring Access to Medication Act of 2019; Final rule on Qualified Business Income Deduction; S. 1149/H.R. 216, the Main Street Tax Certainty Act of 2019

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Drug Enforcement Administration (DEA); Defense, Dept of (DOD); Small Business Administration (SBA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Internal Revenue Service (IRS); SENATE; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Medicare Payment Advisory Commission (MedPAC); White House Office; Office of Management & Budget (OMB); Office of Natl Drug Control Policy (NDCP); Substance Abuse & Mental Health Services Administration (SAMHSA); Government Accountability Office (GAO)

Bills named: S. 1089 (116th), H.R. 216 (116th), H.R. 1922 (116th), H.R. 1398 (116th), S. 1149 (116th), S. 172 (116th), H.R. 218 (116th), S. 215 (116th)

Pharmacy PHA

H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019;

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Small Business Administration (SBA); Food & Drug Administration (FDA); Office of Natl Drug Control Policy (NDCP); Substance Abuse & Mental Health Services Administration (SAMHSA); Internal Revenue Service (IRS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; White House Office; Defense, Dept of (DOD); Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Labor, Dept of (DOL); SENATE; Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1532 (116th), H.R. 3223 (116th), H.R. 2376 (116th), H.R. 1959 (116th), S. 1227 (116th)

Labor Issues/Antitrust/Workplace LBR

Final rule, "Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees"

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); White House Office; Drug Enforcement Administration (DEA); Internal Revenue Service (IRS); SENATE; Office of Management & Budget (OMB); Office of Natl Drug Control Policy (NDCP); Small Business Administration (SBA); Substance Abuse & Mental Health Services Administration (SAMHSA); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS)

Defense DEF

Tricare pharmacy issues

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); Office of Natl Drug Control Policy (NDCP); Food & Drug Administration (FDA); White House Office; Labor, Dept of (DOL); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Substance Abuse & Mental Health Services Administration (SAMHSA); Small Business Administration (SBA); SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Alcohol and Drug Abuse ALC

H.R. 127, CARERS Act of 2019; H.R. 171, the Legitimate Use of Medical Marihuana Act; H.R. 1845, ALERT Act of 2019; S. 516, Prescription Drug Monitoring Act of 2019; H.R. 1588, Ending Federal Marijuana Prohibition Act of 2019; Implementation of pharmacy provisions of Public Law No: 115-271; Implementation of Hemp provisions of Public Law No: 115-334

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Government Accountability Office (GAO); Food & Drug Administration (FDA); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Medicare Payment Advisory Commission (MedPAC); Substance Abuse & Mental Health Services Administration (SAMHSA); Small Business Administration (SBA); Labor, Dept of (DOL); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA)

Bills named: H.R. 1588 (116th), H.R. 1845 (116th), H.R. 127 (116th), S. 516 (116th), H.R. 171 (116th)

Medicare/Medicaid MMM

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Office of Natl Drug Control Policy (NDCP); Food & Drug Administration (FDA); Internal Revenue Service (IRS); Defense, Dept of (DOD); Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; White House Office; Government Accountability Office (GAO); Medicare Payment Advisory Commission (MedPAC); Small Business Administration (SBA); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 1034 (116th), S. 2447 (116th), H.R. 1781 (116th), H.R. 107 (116th), H.R. 1346 (116th), S. 377 (116th), S. 773 (116th), H.R. 1046 (116th), H.R. 1384 (116th), H.R. 1035 (116th), H.R. 2113 (116th), S. 814 (116th), S. 475 (116th), S. 801 (116th), H.R. 275 (116th), S. 476 (116th), H.R. 803 (116th), H.R. 3417 (116th), H.R. 366 (116th), S. 205 (116th), S. 691 (116th), S. 62 (116th), S. 1129 (116th), H.R. 2115 (116th), S. 551 (116th), H.R. 1323 (116th), S. 640 (116th), S. 99 (116th), S. 988 (116th), H.R. 448 (116th), S. 1384 (116th), H.R. 937 (116th), S. 2771 (116th), H.R. 3408 (116th)

Health Issues HCR

S. 474, Stop the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act; H.R. 447 / S. 97, Affordable and Safe Prescription Drug Importation Act; S. 61 / H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 102 / H.R. 465, Prescription Drug Price Relief Act of 2019; H.R.1478, Affordable Insulin Act of 2019; S. 3, Keeping Health Insurance Affordable Act of 2019; H.R 965 / S. 340, CREATES Act of 2019; H.R. 1332, Fair Care Act of 2019; S. 637, CURE High Drug Prices Act; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 657, A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits; S. 709, Prescription Drug Pricing Dashboard Act; S. 977, Transparent Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 2296, FAIR Drug Pricing Act of 2019; H.R. 3947, the Competition Prescription Act of 2019; H.R. 2279, the Safe Step Act; H.R. 3, the Lower Drug Costs Now Act of 2019; S. 2543, the Prescription Drug Pricing Reduction Act of 2019

LobbyistCovered position, as disclosed
ANNE CASSITY —
PHILLIP ADAM HARBISON —
RONNA HAUSER —
KARRY LA VIOLETTE —
KALA SHANKLE —
REEMA TANEJA —

Contacted: Labor, Dept of (DOL); Drug Enforcement Administration (DEA); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Small Business Administration (SBA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); White House Office; Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Management & Budget (OMB); Office of Natl Drug Control Policy (NDCP)

Bills named: H.R. 2279 (116th), H.R. 3947 (116th), S. 657 (116th), S. 474 (116th), S. 3 (116th), S. 340 (116th), H.R. 965 (116th), S. 97 (116th), S. 1895 (116th), H.R. 1478 (116th), H.R. 478 (116th), H.R. 1332 (116th), H.R. 447 (116th), H.R. 2296 (116th), H.R. 3 (116th), H.R. 1499 (116th), S. 637 (116th), H.R. 465 (116th), S. 2543 (116th), S. 709 (116th), S. 102 (116th), S. 977 (116th), S. 61 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.